Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas, a clinical-stage biotechnology company, announced participation in two virtual investor conferences. The first is the Cowen & Co. 42nd Annual Health Care Conference on March 7, featuring a fireside chat with Chief Scientific Officer Ian Taylor. The second event is the Guggenheim Targeted Protein Degradation Day on March 16, also with Taylor. Arvinas focuses on developing therapies that degrade disease-causing proteins using its PROTAC technology. The company has three clinical-stage programs targeting advanced prostate and breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) reported its financial results for Q4 and the full year 2021, highlighting significant advancements in its drug development pipeline and a strong collaboration with Pfizer.
The company reported revenues of $46.7 million for 2021, up from $21.8 million in 2020, primarily driven by the ARV-471 collaboration. However, the net loss increased to $191 million due to rising R&D costs of $180.4 million. Key milestones are anticipated in 2022 for both ARV-471 and bavdegalutamide, including pivotal trials.
Arvinas, Inc. (Nasdaq: ARVN) announced promising Phase 1 and interim Phase 2 data for its investigational drug bavdegalutamide (ARV-110), targeting metastatic castration-resistant prostate cancer (mCRPC). The treatment showed a 46% prostate-specific antigen (PSA)50 response rate in patients with specific androgen receptor mutations. Additionally, two patients had confirmed durable tumor responses. Arvinas plans to seek FDA discussions for an accelerated approval pathway and aims to initiate a pivotal trial by the end of 2022.
Cardurion Pharmaceuticals has appointed Marcia Moore as Chief Operating Officer. With over 30 years in the pharmaceutical and biotechnology sectors, Moore joins from Arvinas (NASDAQ: ARVN), where she played a crucial role in strategic operations and clinical development. Her expertise includes managing clinical trials and regulatory strategies, enhancing Cardurion’s pipeline of cardiovascular drug candidates, including a $300 million investment from Bain Capital to fuel growth. CEO Peter Lawrence expressed confidence in Moore’s leadership at this pivotal time.
Arvinas announced promising data for bavdegalutamide, showing a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) with AR T878X/H875Y mutations. A pivotal trial is set to begin by year-end 2022, targeting patients who have progressed after novel hormonal agents. Updated data will be presented at the ASCO GU symposium, and a webcast will follow on February 17, 2022.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences in February 2022. The first is the Guggenheim Oncology Conference on February 10, featuring Chief Scientific Officer Ian Taylor. The second is the 2022 SVB Leerink Global Healthcare Conference on February 18, with insights from President and CEO John Houston. Live webcasts of both presentations will be accessible on the company's website.
Arvinas aims to revolutionize treatments for serious diseases through innovative therapies targeting disease-causing proteins.
Arvinas and Pfizer have announced promising updates on ARV-471, a novel estrogen receptor degrader for treating ER+/HER2- breast cancer, presented at the San Antonio Breast Cancer Symposium. Latest Phase 1 data shows a clinical benefit rate of 40% among heavily pretreated patients, with three confirmed partial responses. The drug shows favorable tolerability, with 89% ER degradation. Phase 3 clinical trials are anticipated to begin in 2022, supporting ARV-471's potential as a new standard of care.
Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced updated safety and efficacy data from the Phase 1 trial of ARV-471, an oral estrogen receptor-targeting PROTAC protein degrader. The presentation will take place at the San Antonio Breast Cancer Symposium on December 10, 2021. ARV-471 is aimed at treating locally advanced or metastatic ER+/HER2- breast cancer. Preclinical studies indicated strong tumor shrinkage and ER degradation. Arvinas and Pfizer share development costs and profits as part of their collaboration.
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), has announced that its CFO Sean Cassidy and CSO Ian Taylor will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference. This event is scheduled for November 16 at 10:40 a.m. ET. A live audio webcast of the presentation will be available on Arvinas’ website, with a replay accessible for 30 days post-event.
Arvinas focuses on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® platform, targeting prostate and breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) announced its Q3 2021 financial results, highlighting key advancements in drug development and a strategic collaboration with Pfizer. The company reported cash reserves of $1.55 billion, a significant increase from $688.5 million at the end of 2020, largely due to the Pfizer collaboration. Revenues rose to $9.3 million, driven by collaboration agreements. However, net loss widened to $46.8 million, influenced by rising R&D and administrative expenses. Arvinas plans to initiate multiple Phase 3 studies for its lead drug ARV-471 in 2022.